← Back to Search

GLP-1 Receptor Agonist

semaglutide for Obesity

Phase 2
Waitlist Available
Led By Luba Yammine, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, cardiovascular disease, dyslipidemia, or obstructive sleep apnea
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to week 28
Awards & highlights

Study Summary

This trial will explore how a drug can help people lose weight and quit smoking.

Who is the study for?
This trial is for adults who smoke more than 5 cigarettes a day, want to quit smoking within a month, and are overweight or obese. They must be willing to follow the study procedures and use contraception if applicable. People with diabetes, severe kidney disease, recent heart issues, uncontrolled blood pressure, certain cancers in the last 5 years, or gastrointestinal diseases cannot join.Check my eligibility
What is being tested?
The trial tests whether semaglutide can help manage weight gain after quitting smoking. Participants will receive either semaglutide or a placebo alongside nicotine patches and brief counseling for smoking cessation to see how it affects their weight and appetite control.See study design
What are the potential side effects?
Semaglutide may cause digestive problems like nausea or diarrhea, potential inflammation of the pancreas (pancreatitis), allergic reactions at injection sites, changes in blood sugar levels even without diabetes history; nicotine patches might cause skin irritation or sleep disturbances.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is over 30, or it's over 27 with a condition like high blood pressure, heart disease, high cholesterol, or sleep apnea.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to week 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to week 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Body Weight Percent
Secondary outcome measures
Change in body fat mass as measured in kilograms (kg)
Change in body weight as measured in kilograms (kg)
Change in waist circumference as measured in centimeters(cm)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: semaglutideExperimental Treatment3 Interventions
Group II: placeboPlacebo Group3 Interventions

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
320,780 Total Patients Enrolled
27 Trials studying Obesity
15,209 Patients Enrolled for Obesity
Luba Yammine, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
3 Previous Clinical Trials
303 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is there an upper age limit for enrolling in this experiment?

"Per the requirements of this particular experiment, patients must be aged between 18 and 75. 204 trials are being conducted for individuals below the age of consent, while 795 studies involve geriatric participants."

Answered by AI

What perils have been identified with the application of semaglutide?

"There is preliminary evidence backing the safety of semaglutide, therefore it was awarded a rating of 2 on our scale. However, since this trial is in Phase 2, efficacy has yet to be confirmed."

Answered by AI

Am I eligible to apply for inclusion in this experiment?

"To qualify for this research trial, participants must meet the criteria of being aged between 18 and 75 with a diagnosis obesity. This particular study is looking to enroll 197 people in total."

Answered by AI

Are there still spaces available for individuals to partake in this experimental procedure?

"Evidence found on clinicaltrials.gov suggests that this trial is not currently considering applicants, even though it was originally posted in March of 2024 and last modified a year later. Although the study has reached its quota, 1246 other medical trials are still recruiting participants at this time."

Answered by AI

Who else is applying?

What site did they apply to?
The University of Texas Health Science Center at Houston
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I'm hoping new clinical trials can help me. This trial can help me medically, and educate me .Better my quality of living.
PatientReceived no prior treatments
Recent research and studies
clinicaltrials.govStudy
Semaglutide for Post-Smoking Cessation Weight Management
Luba Yammine 2024. "Semaglutide for Post-Smoking Cessation Weight Management". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06173778.
All > Smoking > Overweight
~131 spots leftby Jul 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top